Overall, the graph shows IFN- α2b was associated with a faster reduction on the proportion of virus positive patients.  

Survival Curve Comparing COVID-19 Viral Clearance in Patients Receiving IFN- α2b Treatment to those Receiving ARB Treatments

Methods used in Interferon-α2b treatment for COVID-19 article 

 - Overall, results showed that IFN- α2b was associated with accelerated viral clearance. 

- The IFN- α2b only treatment group had a mean time to viral clearance of 21.1 days.

- The Arbidol (ARB) only treatment group had a mean time to viral clearance of 27.9 days. 

- The IFN- α2b and ARB treatment group had a mean time to viral clearance of 20.3 days.


University of Michigan - Ann Arbor

- Effects of IFN-α2b on viral clearance
- Effects of IFN-α2b on inflammatory markers 

Findings in favor of treating COVID-19 infections with Interferon-α2b

Zhou Q, Chen V, Shannon C et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01061

https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full

Interferon-α2b Treatment for COVID-19

- Treatment with IFN- α2b was associated with reduced levels of IL-6 and CRP.

- Viral clearance was also correlated with a reduction in inflammatory markers.


Learn Before

Related

Learn After